ATE407207T1 - Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung - Google Patents

Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung

Info

Publication number
ATE407207T1
ATE407207T1 AT95939723T AT95939723T ATE407207T1 AT E407207 T1 ATE407207 T1 AT E407207T1 AT 95939723 T AT95939723 T AT 95939723T AT 95939723 T AT95939723 T AT 95939723T AT E407207 T1 ATE407207 T1 AT E407207T1
Authority
AT
Austria
Prior art keywords
nervous system
peripheral nervous
methods
encodes
dna
Prior art date
Application number
AT95939723T
Other languages
English (en)
Inventor
Gail Mandel
Simon Halegoua
Laurence A Borden
Original Assignee
Trophix Pharm Inc
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26989015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE407207(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trophix Pharm Inc, Univ New York State Res Found filed Critical Trophix Pharm Inc
Application granted granted Critical
Publication of ATE407207T1 publication Critical patent/ATE407207T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT95939723T 1994-11-02 1995-11-02 Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung ATE407207T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33402994A 1994-11-02 1994-11-02
US48240195A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ATE407207T1 true ATE407207T1 (de) 2008-09-15

Family

ID=26989015

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95939723T ATE407207T1 (de) 1994-11-02 1995-11-02 Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung

Country Status (13)

Country Link
US (5) US6110672A (de)
EP (2) EP0789575B8 (de)
JP (5) JP2000503521A (de)
AT (1) ATE407207T1 (de)
AU (1) AU697465B2 (de)
CA (1) CA2204355C (de)
DE (1) DE69535830D1 (de)
DK (1) DK0789575T3 (de)
ES (1) ES2314978T3 (de)
MX (1) MX9703187A (de)
NZ (1) NZ296748A (de)
PT (1) PT789575E (de)
WO (1) WO1996014077A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407207T1 (de) 1994-11-02 2008-09-15 Trophix Pharm Inc Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung
US6184349B1 (en) 1995-10-11 2001-02-06 Syntex (Usa) Inc. Cloned peripheral nerve, tetrodotoxin-resistant sodium channel α-subunit
US6030810A (en) * 1997-02-26 2000-02-29 Delgado; Stephen Gregory Cloned tetrodotoxin-sensitive sodium channel α-subunit and a splice variant thereof
EP0875570A3 (de) * 1997-05-01 1999-12-22 Smithkline Beecham Plc Neurodegenerative Polypeptide HHPDZ65
CH693031A5 (de) * 1997-11-20 2003-01-31 Hoffmann La Roche Nucleinsäure, die einen Nervengewebe-Natriumkanal kodiert.
JP2002539832A (ja) * 1999-03-26 2002-11-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４８個のヒト分泌タンパク質
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
EP1252330A2 (de) 1999-11-26 2002-10-30 McGill University Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie
AU2001273888A1 (en) 2000-07-05 2002-01-14 Neurosearch A/S New sodium channel (rnav1.5a) and use thereof
GB0021617D0 (en) * 2000-09-02 2000-10-18 Imp College Innovations Ltd Diagnosis and treatment of cancer
WO2002024722A2 (en) * 2000-09-19 2002-03-28 Prochon Biotech Ltd. Crystalline fgf9 dimer and methods of use
DE10054878A1 (de) * 2000-11-06 2002-05-08 Boehringer Ingelheim Int Natriumkanäle vom Typus der peripheren Nerven
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
WO2003060525A1 (en) * 2002-01-17 2003-07-24 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of the voltage-gated ion channel scn2a for neurodegenerative diseases
US9278088B2 (en) 2002-02-19 2016-03-08 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US7659082B2 (en) * 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US7125676B2 (en) 2002-02-25 2006-10-24 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
WO2004050857A2 (en) * 2002-12-04 2004-06-17 Euro-Celtique S.A. Splice variant of human sodium iii channel (hnaiii18)
JP2006522135A (ja) * 2003-03-31 2006-09-28 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド 喘息およびアレルギーの処置のための両性イオン免疫調節剤
CA2553745A1 (en) * 2004-01-21 2005-08-04 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
US20050201995A1 (en) * 2004-02-05 2005-09-15 Board Of Regents, The University Of Texas System Methods and compositions related to neuronal differentiation
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
JP2010529173A (ja) * 2007-06-14 2010-08-26 ハマースミス・イメイネット・リミテッド 神経活性の測定
CA2773983A1 (en) 2009-09-11 2011-03-17 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
CA2997211A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL137318C (de) 1964-06-09
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4500530A (en) * 1980-11-26 1985-02-19 Boucher John H Method of treating horses to inhibit or reduce increases in crenated red blood cells during exercise
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
WO1990009441A1 (en) 1989-02-01 1990-08-23 The General Hospital Corporation Herpes simplex virus type i expression vector
WO1990009391A1 (en) * 1989-02-13 1990-08-23 Arch Development Corporation Nucleic acid encoding sodium channel protein
US5380836A (en) * 1989-02-13 1995-01-10 Arch Development Corporation Nucleic acid encoding sodium channel protein
ATE140213T1 (de) * 1990-03-08 1996-07-15 Fujisawa Pharmaceutical Co N-monosubstituierte cyclopentenylamine, ein verfahren zu ihrer herstellung, und ihre verwendung als medikament
IE911869A1 (en) 1990-06-01 1991-12-04 Regeneron Pharma A family of map2 protein kinases
ATE181106T1 (de) 1990-09-28 1999-06-15 Hoffmann La Roche Mutationen in der 5'-3'-exonukleaseaktivität thermostabiler dna-polymerasen
WO1992006693A1 (en) 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
WO1993003743A1 (en) 1991-08-16 1993-03-04 The General Hospital Corporation Method of gene delivery to post-mitotic cells
US5356777A (en) * 1992-10-01 1994-10-18 University Of Pittsburgh Methods of detecting periodic paralysis in horses
US5338671A (en) 1992-10-07 1994-08-16 Eastman Kodak Company DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
US5340728A (en) 1992-12-09 1994-08-23 E. I. Du Pont De Nemours And Company Method for amplification of targeted segments of nucleic acid using nested polymerase chain reaction
WO1994014978A1 (de) 1992-12-18 1994-07-07 Strack Hans B Verbesserte ausbeuten von pcr-produkten in gegenwart von dna-einzelstrang bindendem protein und dessen präparation aus thermus flavus
ATE407207T1 (de) 1994-11-02 2008-09-15 Trophix Pharm Inc Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung

Also Published As

Publication number Publication date
DE69535830D1 (de) 2008-10-16
JP2003047484A (ja) 2003-02-18
US20090029415A1 (en) 2009-01-29
MX9703187A (es) 1998-02-28
EP0789575A1 (de) 1997-08-20
US20090203122A1 (en) 2009-08-13
PT789575E (pt) 2008-12-15
DK0789575T3 (da) 2009-01-12
AU4143496A (en) 1996-05-31
US6110672A (en) 2000-08-29
EP1985703A2 (de) 2008-10-29
US20030092645A1 (en) 2003-05-15
US8012748B2 (en) 2011-09-06
EP1985703A3 (de) 2009-04-08
EP0789575A4 (de) 2000-11-08
NZ296748A (en) 1999-11-29
JP2007169286A (ja) 2007-07-05
AU697465B2 (en) 1998-10-08
US20040229792A1 (en) 2004-11-18
JP2009118844A (ja) 2009-06-04
EP0789575B1 (de) 2008-09-03
EP0789575B8 (de) 2009-01-14
US6703486B2 (en) 2004-03-09
CA2204355C (en) 2001-01-16
CA2204355A1 (en) 1996-05-17
ES2314978T3 (es) 2009-03-16
WO1996014077A1 (en) 1996-05-17
JP2000503521A (ja) 2000-03-28
JP2009055921A (ja) 2009-03-19

Similar Documents

Publication Publication Date Title
ATE407207T1 (de) Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung
Shoyab et al. Structure and function of human amphiregulin: a member of the epidermal growth factor family
DE69739860D1 (de) Rekombinante AAV zur Herstellung eines Medikaments für die Gentherapie von Muskelzellen
RU95115239A (ru) Аналог эритропоэтина
DK0559884T4 (da) Rekombinante virusvektorer til ekspression i muskelceller
NO934235L (no) Anvendelse av nukleinsyreanaloger for diagnostiske og analytiske fremgangsmaater
ATE338821T1 (de) Strukturprotein von aav, seine herstellung und verwendung
PT84089B (pt) Sequencias de adn codificando para proteinas possuindo a actividade biologica dos inibidores de husi-tipo i, processos biotecnologicos para a preparacao das referidas proteinas e de composicoes farmaceuticas contendo as referidas proteinas
ATE85345T1 (de) Neues cadiodilatin-fragment, prozess zu dessen herstellung und dessen anwendung.
AR003961A1 (es) Moleculas de acido nucleico
MXPA00006306A (es) Compuestos del canal de ion del cerebro o corazon, regulados por nucleotidos ciclicos y usos de los mismos.
BR9812791A (pt) Sequências de ácido nucléico associadas à virulência e seu uso
DE69434961D1 (de) Funktion und aktivität des viralen proteins r (vpr)
ES2170747T3 (es) Analogos superiores de trombomodulina para uso farmaceutico.
DK0804467T3 (da) Isolerede, trunkerede nukleinsyremolekyler, som koder for GAGE-tumorafstødningsantigen
EP0815240A4 (de) Neue menschliche proteine, die cyclinebhängigen kinasen ähneln, sowie methoden zu deren verwendung
EA200500661A1 (ru) Катионный аналог кардиолипина (варианты), его применение (варианты), композиция и набор для трансфекции клеток (варианты)
ATE26710T1 (de) Substituierte tert.-butanol-derivate, verfahren zu ihrer herstellung und diese enthaltende antimykotische mittel.
ATE317021T1 (de) Antisense modulierung von lfa-3
FR2766183B1 (fr) Medicaments contenant des polyhydroxybutylpyrazines, les polyhydroxybutylpyrazines nouvelles et leur preparation
PT914417E (pt) Dnase ii humana
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
KR950003312A (ko) 연골세포 단백질
EP0854186A3 (de) Zellteilungs-Gen DivIB von Staphylococcus aureus
DE60119385D1 (de) Antagonisten der defektiven magnesiumbindung als therapeutische mittel und methoden zur behandlung von abnormalen physiologischen zuständen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0789575

Country of ref document: EP